|Dongsheng Pharmaceutical International Co Ltd -- USA Stock|| |
USD 0.01 0.00 0.00%
Chief Devel. Officer
Mr. Di Wu is the Chief Development Officer of Dongsheng Pharmaceutical International Co Ltd. He is the President and Founder in GoodeePharma Suzhou, China since 2008. From 2002 to 2008, Mr. Wu served as Core Management in the Division of Medical Genetics in University of Pennsylvania, Philadelphia, PA and focused on DMPK, Histology and Morphology. From 2000 to 2002, he was the Post Doctor in the Department of Molecular Genetics, The Wistar Institute, and Philadelphia, PA and focused on Molecular Biology
Age: 44 Executive Since 2010 Ph.D
86 10 8858 0708
Wu graduated from the School of Medicine of Soochow University as a Medicine Doctor in 1991.
The company has return on total asset (ROA)
of 14.01 %
which means that it generated profit of $14.01 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 34.37 %
meaning that it created $34.37 on every $100 dollars invested by stockholders.
Dongsheng Pharmaceutical International Co., Ltd. Dongsheng Pharmaceutical International Co Ltd (DNGH) is traded on OTC Market in USA. It is located in Dongsheng Pharmaceutical International Co., Ltd.Floor , NoBeijing, and employs 69 people.